Boardroom Briefing

Jazz Pharma reports strong growth.

10th August, 2014

Jazz Pharma reports strong growth

Jazz Pharmaceuticals reported strong growth in its second quarter last week, as revenues rose due to accelerating sales of sleep drug Xyrem and its new anticoagulant defibrotide. The firm reported revenue of $291.2 million, up almost 40 per cent year on year. Jazz also reported adjusted net profit of $128 million, or $2.05 a share, a figure which was ahead of expectations.

Jazz has updated its guidance for the full year, with revenue now...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader

Trial

€1

Unlimited Access for 1 Month

Get basic

*New subscribers only

You can cancel any time.

Annual

€200

€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.

Quarterly

€55

€42

90 Day Pass

You can cancel any time.

2 Yearly

€315

€248

Unlimited Access for 2 Years

You can cancel any time.

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

The year in review

Legacy Richie Oakley 1 year ago

Newsround: What Thursday’s papers say

Legacy Leanna Byrne 5 years ago

More cycle routes, expansion of Luas to Bray and new bus network proposed

Legacy Digital Desk 5 years ago